Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: study protocol for an investigator-initiated phase 2 trial (NapaSinti trial)

BACKGROUND: Biliary tract cancer (BTC) is a relatively rare but highly aggressive malignancy. However, there is currently no satisfactory second-line regimen for patients without specific genetic mutations. Nanoparticle albumin–bound paclitaxel, also known as nab-paclitaxel (Abraxane, Bristol Myers...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Nan, Li, Xiaofen, Yang, Yu, Tan, Sirui, Zhang, Shunyu, Huang, Qiyue, Gou, Hongfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405505/
https://www.ncbi.nlm.nih.gov/pubmed/37550655
http://dx.doi.org/10.1186/s12885-023-11188-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405505/
https://www.ncbi.nlm.nih.gov/pubmed/37550655
http://dx.doi.org/10.1186/s12885-023-11188-4

Ejemplares similares